Please login to the form below

Not currently logged in
Email:
Password:

Bentley wins US intranasal technology patent protection

Bentley Pharmaceuticals has revealed that the US Patent and Trademark Office issued it with patent protection on its intranasal technology

US-based specialty pharmaceutical company, Bentley Pharmaceuticals, has received US Patent and Trademark Office recognition through the award of patent number 7,244,703 entitled "Pharmaceutical Compositions and Methods for Peptide Treatment."

The patent extends coverage for Bentley's current intranasal drug delivery technology employing CPE-215 beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins.

In September 2006, Bentley received a US patent covering its intranasal delivery spray for insulin.

The new patent, which was issued from an application filed back in 2004, provides proprietary protection to Bentley for 20 years from the date of filing.

23rd July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics